Kuros Biosciences Ltd.
Develops biologic technologies for tissue repair and bone regeneration.
KURN | SW
Overview
Corporate Details
- ISIN(s):
- CH0325814116
- LEI:
- 5299006U5POB2AVTT709
- Country:
- Switzerland
- Address:
- Wagisstraße 25, 8952 Schlieren
- Website:
- https://kurosbio.com/
- Sector:
- Manufacturing
Description
Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2013-09-09 07:00 |
Cytos Biotechnology Ltd (SIX:CYTN) today presents additional results from its P…
|
English | 13.9 KB | ||
| 2013-08-06 07:00 |
Cytos Biotechnology Ltd: Second Quarter Report 2013 / Highlights
|
English | 13.8 KB | ||
| 2013-06-28 19:00 |
Cytos Biotechnology Ltd, Annual Shareholders' Meeting: Shareholders approved al…
|
English | 6.8 KB | ||
| 2013-06-06 07:00 |
Cytos Biotechnology Ltd invites to the Annual Shareholders' Meeting 2013 (with …
|
English | 6.9 KB | ||
| 2013-05-17 07:00 |
Cytos Biotechnology Ltd announced that A*STAR and Cytos bring Singapore's first…
|
English | 15.5 KB | ||
| 2013-04-25 07:00 |
Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent…
|
English | 13.3 KB | ||
| 2013-03-13 07:00 |
Cytos Biotechnology AG: The Journal of Allergy and Clinical Immunology publishe…
|
English | 10.6 KB | ||
| 2013-03-12 07:00 |
Cytos Biotechnology Strengthens Management Team
|
English | 10.5 KB | ||
| 2013-02-14 07:15 |
Cytos Biotechnology Ltd announces full year 2012 financial results
|
English | 7.5 KB | ||
| 2013-02-04 07:00 |
Cytos VLP Platform is Basis for Phase 1 Clinical Trial with Anti-lgE Vaccine
|
English | 7.2 KB | ||
| 2013-01-23 07:15 |
Cytos to regain rights to Smoking Cessation Vaccine
|
English | 7.0 KB | ||
| 2013-01-16 07:00 |
Cytos provides update of Phase 2b clinical trial of CYT003 in allergic asthma
|
English | 7.4 KB | ||
| 2012-11-20 17:46 |
Extraordinary Shareholders' Meeting of Cytos Biotechnology Ltd: Shareholders ap…
|
English | 8.9 KB | ||
| 2012-11-06 07:00 |
Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent De…
|
English | 10.7 KB | ||
| 2012-10-26 18:00 |
Cytos Biotechnology Ltd invites for an Extraordinary Shareholders' Meeting
|
English | 9.2 KB |
Automate Your Workflow. Get a real-time feed of all Kuros Biosciences Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Kuros Biosciences Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kuros Biosciences Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-23 | N/A | Executive member | Sell | None | 1,264,800.00 CHF |
| 2025-04-17 | N/A | Executive member | Sell | None | 13,344.49 CHF |
| 2025-03-18 | N/A | Non-Executive member | Buy | None | 38,200.00 CHF |
| 2024-12-11 | N/A | Executive member | Sell | None | 4,702,500.00 CHF |
| 2024-11-15 | N/A | Non-Executive member | Buy | None | 925,210.00 CHF |
| 2024-11-14 | N/A | Non-Executive member | Sell | None | 592,000.00 CHF |
| 2024-11-12 | N/A | Executive member | Sell | None | 13,890.86 CHF |
| 2024-09-25 | N/A | Executive member | Sell | None | 8,226,000.00 CHF |
| 2024-09-25 | N/A | Non-Executive member | Sell | None | 3,656,000.00 CHF |
| 2024-09-24 | N/A | Non-Executive member | Buy | None | 223,720.00 CHF |
Peer Companies
